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Current concepts of the management of dental extractions
for patients taking warfarin
G Carter,* AN Goss,† J Lloyd,‡ R Tocchetti§
Abstract
Background: Controversy has surrounded the
correct management of patients therapeutically
anticoagulated with warfarin who require dental
extractions. The risk of bleeding must be weighed up
against the risk of thromboembolism when deciding
whether to interfere with a patient’s warfarin
regimen. An improved understanding of the
importance of fibrinolytic mechanisms in the oral
cavity has resulted in the development of various
local measures to enable these patients to be treated
on an outpatient basis.
Methods: A review of the literature was undertaken.
This was supplemented by the authors’ clinical trials
and extensive clinical experience with
anticoagulated patients.
Results: Various protocols for treating patients
taking warfarin have been reviewed and summarized
and an overview of the haemostatic and fibrinolytic
systems is presented. A protocol for management of
warfarinized patients requiring dental extractions in
the outpatient setting is proposed.
Conclusions: Patients therapeutically anticoagulated
with warfarin can be treated on an ambulatory
basis, without interruption of their warfarin regimen
provided appropriate local measures are used.
Key words: Warfarin, anticoagulation, extractions, oral
surgery.
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treatment, the number of such patients requiring dental
extractions is on the rise. Patients receiving warfarin
who undergo dental extractions may have prolonged
and excessive haemorrhage.1-8 The clinician who is
faced with a warfarinized patient requiring extractions
has to balance the risk of reducing or stopping the
anticoagulant therapy with that of excessive bleeding.
Traditionally emphasis has been given to stopping
bleeding by altering the warfarin dosage. However,
cessation or decrease in the anticoagulant therapy
exposes the patients, especially those with artificial
heart valves, to the risk of thromboembolism.9-14 Most
patients and health professionals, when given the
choice of some oral bruising or oozing versus potential
stroke or similar catastrophic event, choose not to risk
stopping their anticoagulant. Various protocols have
been suggested for dental extraction in anticoagulated
patients.15 There is no standard therapeutic approach to
these patients and it appears that each patient’s
treatment plan is tailored by their cardiologist, local
medical officer, and dentist. In support of the
hypothesis that impaired haemostasis is the result of
either deficient coagulation (impaired fibrin deposition)
or increased fibrinolysis (fibrin resolution), local
measures to inhibit fibrinolysis have evolved and
enabled dental extractions to now be performed in
therapeutically warfarinized patients on an outpatient
basis.
Overview of the haemostatic and fibrinolytic systems
In connection with vascular injury, the integrity of
the vascular system is maintained by the haemostatic
mechanism. Through this physiologic mechanism,
haemorrhage is arrested at the site of injury between
four biological systems: the vessel wall, the platelets,
and the coagulation and fibrinolytic systems (Fig 1).
The vessel wall
When a vessel is injured, vasoconstriction occurs as
an early event, in order to reduce the blood flow and
extravasation of blood components. The
vasoconstriction of arteries and arterioles is under
neural control, whereas the constriction of smaller
vessels (including capillaries) is controlled by humoral
INTRODUCTION
Warfarin is the most commonly prescribed oral
anticoagulant used to prevent and treat
thromboembolism. Because this is a long-term
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and local factors. Compounds such as adenosine
diphosphate (ADP), serotonin and Thromboxane A2,
released from platelets, potentiate vasoconstriction.16
The platelets
When platelets are exposed to an injured vessel wall,
they will adhere to the thrombogenic subendothelial
structures and in particular to perivascular collagen.
Von Willebrand factor, fibronectin and fibrinogen
present in plasma, as well as in a granules in platelets,
bind to the platelet membrane, and are important for
platelet adhesion. Platelets are initially activated by
substances such as ADP, adrenaline, serotonin,
thrombin, platelet activating factor, and collagen,
which bind to the platelet membrane and change its
surface morphology. This is followed by granular
secretion and activation. The activated platelets
participate in the coagulation process and provide a
surface for assembly, activation and binding of
coagulation proteins subsequently activated in a
sequential manner.17 Platelet adhesion is followed by a
continuous aggregation mediated by ADP,
thromboxanes and prostaglandins. The aggregated
platelets form the platelet plug, which is responsible for
immediate (primary) haemostasis. This platelet plug
appears to serve as a surface for the formation of a clot
where the blood coagulation factors are active. The clot
and the platelet plug are necessary for effective
haemostasis. The bleeding time is used to test primary
haemostasis.
The coagulation system
The coagulation system converts the plasma protein
fibrinogen into fibrin by the enzyme thrombin. The
process includes several reactions occurring in a
cascading-like manner, and can be initiated by two
different pathways, the intrinsic pathway (factor XII-
dependent) and the extrinsic pathway (thromboplastin-
dependent). While the two systems differ in methods of
activating the coagulation system, they share a
common pathway for production of fibrin. In the
intrinsic system, a circulating surface-sensitive protein,
the Hageman factor (factor XII), is activated on contact
with a foreign surface. This contact (and subsequent
reaction) initiates the coagulation cascade. Factor XII
can be activated by contact with collagen, vascular
basement membrane, activated platelets, or
phospholipids from platelets. The process ultimately
results in the polymerization of fibrin, which is then
stabilized by factor XIII. The intrinsic pathway is
assessed by the activated partial thromboplastin time
(APTT). In the extrinsic system tissue thromboplastin
elaborated at the site of tissue injury forms complexes
with factors V, VII, and X in the presence of calcium
ions to convert prothrombin to thrombin. This system
also facilitates aggregation of platelets and enhances
the activity of the intrinsic system.18 The extrinsic
system is assessed by the International Normalized
Ratio (INR) or prothrombin time (PT).
The fibrinolytic system
Physiological fibrinolysis has been defined as the
degradation of fibrin by the enzyme plasmin. The
conversion of the zymogen plasminogen to the active
enzyme plasmin is a fundamental phase in the
activation process. Plasminogen is a circulating plasma
protein produced in the liver that is activated by two
different pathways of which the extrinsic fibrinolytic
system is dependent on activators bound in the tissues
(tissue plasminogen activator-t-PA), and the intrinsic
fibrinolytic system on humoral precursors circulating in
the blood. Activation of the pathways results in the
conversion of plasminogen to plasmin. 
The possible pathogenic role of local fibrinolysis in
the oral cavity on bleeding after oral surgery in healthy
individuals, as well as patients with defects of the
coagulation system has been suggested by several
authors.19-20 Fibrin deposited in the oral cavity can be
resolved both by the activation of blood fibrinolysis as
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Fig 1. Interaction between the haemostatic and fibrinolytic systems.
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well as by the plasminogen activators in the oral
environment. An increased fibrinolytic activity in the
fluid from gingival crevices in patients with periodontal
disease, as compared to subjects with healthy gingiva,
has previously been reported.21 The presence of
activators of fibrinolysis associated with oral epithelial
cells and in the saliva has also been demonstrated,19,22-27
as has the absence of inhibitors of fibrinolysis in the
saliva.28-29
Warfarin
Warfarin is a vitamin K antagonist that impairs the
liver synthesis of coagulation factors II, VII, IX and X,
and endogenous proteins C and S affecting both the
intrinsic and extrinsic coagulation pathways, resulting
in impaired fibrin formation.
Indications for use
Oral anticoagulants such as warfarin are considered
effective in the prophylaxis and treatment of venous
thromboembolism,30-31 and for the prevention of
systemic emboli from a cardiac source.32 The aim of
anticoagulant therapy is to reduce the coagulability of
blood into an optimal therapeutic range within which
the patient is protected against thrombosis at the cost
of being exposed to a small risk of spontaneous
bleeding. Commonly accepted indications for warfarin
treatment and the aims of treatment are summarized in
Table 1.
Pharmacokinetics
Warfarin is rapidly absorbed from the upper
gastrointestinal tract, and is highly protein bound but it
is the free fraction only that is pharmacologically
active. The half-life is independent of the dose but
usually falls within the range of 35-45 hours. Warfarin
is distributed to approximately 8 to 27 per cent of the
body weight, which is similar to that of albumin (to
which it is bound). Warfarin is completely metabolized
by the liver and subsequently eliminated by the kidneys. 
Monitoring – Prothrombin time test/INR
Since the early 1940s the PT method developed by
Quick has been the primary means of monitoring 
the level of anticoagulant control.33 The test is
performed by adding thromboplastin to citrated 
patient blood. By the late 1970s there were many
commercial thromboplastins available, with differing
levels of sensitivity. Subsequently, in 1978, the World
Health Organization (WHO) recommended that the 
PT be standardized. In 1983, the WHO published the
recommendations for reporting the level of
anticoagulation using an INR. The INR was developed
to normalize the PT test based on the sensitivity of
different thromboplastins. As a result, an INR is
essentially the same regardless of which thromboplastin
a particular laboratory uses. An INR of 1 corresponds
with a normal haemostatic capacity. Therapeutic levels of
anticoagulation are reached with INR values between 2
and 3.5. When the INR is 5 or higher, there is a serious
risk of spontaneous bleeding episodes. In 1986, an Ad
Hoc committee sponsored by the American College of
Chest Physicians (AACP) and the National Heart, Lung
and Blood Institute formulated new guidelines for
anticoagulation.34 The committee reviewed the
literature and clinical findings and determined that
patients could be treated with lower doses of warfarin
than used previously to prevent thrombosis and at the
same time minimize complications associated with
anticoagulation (Table 2). Some investigators still
recommend higher levels of anticoagulation.35
Complications of warfarin therapy
Complications include bleeding, drug interactions,
overdose and rare non-haemorrhagic side effects. By far
Table 1. Commonly accepted indications for oral
anticoagulant treatment, and aims of treatment
1. Venous thrombosis and pulmonary embolism:
Primary prevention
Treatment of established thrombosis
Secondary prevention
2. Myocardial infarction:
Prevention of venous thromboembolism
Prevention of systemic embolism
Prevention of re-infarction
3. Valvular heart disease, prosthetic heart valves, cardiac
arrhythmia and cardiomyopathy:
Prevention of systemic embolism
4. Systemic embolism:
Secondary prevention
5. Transient cerebral ischaemia:
Prevention of recurrent transient ischaemia
Prevention of stroke
6 Reconstructive artery surgery and atherosclerotic peripheral
vascular disease:
Prevention of thrombotic occlusion
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Adapted from Hirsch et al. 1992.35
the most common complication is bleeding, most
commonly simple bruising or haematuria, but bleeding
can also be gastrointestinal, intracranial,
retroperitoneal and in other sites. Spontaneous bleeding
is likely to occur when the INR is excessively
prolonged. An excessive INR can be returned to the
therapeutic range by either withholding warfarin for
one to two days, administering low doses of vitamin K
(0.5-5mg slow iv injection), or infusing a concentrated
factor replacement or fresh frozen plasma.
Warfarin is subject to many drug interactions, which
may increase or decrease its anticoagulant effect.
Important drugs commonly encountered in dentistry
and their effects on the INR in patients taking warfarin
are summarized in Table 3.
Dental extractions and warfarin
The controversy surrounding patients taking
warfarin who require dental extractions centres on the
decision whether to continue or withdraw the
medication prior to surgery. Four different philosophies
can be distinguished.
1) No change in the warfarin therapy
It is clear that continuity and consistency of a
regimen of anticoagulation are beneficial to all patients
who require such therapy. Several authors in the past
have published reports recommending leaving the
anticoagulant dose unaltered for simple oral surgical
procedures such as dental extractions.2,7,36-40 According
to these authors, the small but potentially hazardous
effect of discontinuing anticoagulant therapy is not
justified in patients’ anticoagulated within the
therapeutic range. However, a closer look at the study
populations on which these conclusions were based
discloses that in the majority of cases with few or no
problems post-operatively, PT values (INR not yet in
use) were either on the low side of the therapeutic range
or were virtually normal. The most recent literature has
recommended that dental extractions can be safely
performed in patients therapeutically anticoagulated
with warfarin, without the need for topical or regional
medication to enhance or stabilize clot formation at the
surgical site.41-43 Further controlled studies using large
patient groups are required before this technique can be
safely advocated.
2) No change in the warfarin therapy plus local
measures
A variety of procedures to secure local haemostasis
have been suggested in the literature. The large
variation in these procedures indicates a lack in
consensus of treatment methods, probably because the
suggested methods led to an insufficient reduction in
the bleeding complications following dental
extractions. A sound surgical technique takes priority
when extracting teeth in all patients whether they are
taking warfarin or not. Steps to encourage local
clotting include: constant application of pressure to the
involved tissues even when, for example, a tooth is
being luxated; +/- placement of an absorbable pack
(e.g., Gelfoam®, Pharmacia and Upjohn, Michigan,
USA, Surgicel®, Ethicon Inc, New Jersey, USA) in 
each socket to help serve as a matrix for clot formation;
+/- placement of sutures under tension; application of
heavy biting pressure in immediate post-operative
period and clear verbal + written instructions with
regard to mouth care and diet in the post-operative
period (Table 4).
The complication of tissue haematoma as a result of
a local anaesthetic injection has not been discussed in
relation to the dental patient receiving warfarin. That
this may be an unrecognized potential problem is
evident from the fact that several authors have reported
ecchymosis, haematomas, or facial swellings as post-
operative complications following dental extractions in
patients receiving oral anticoagulants.2,5,7 However, in
the papers reviewed none of them conjectured as to the
cause of these complications, and none gave specific
information regarding the local anaesthetic
methodology of their protocols. Guidelines developed
for the dental treatment of the haemophiliac patient are
appropriate in making recommendations for treating
the anticoagulated patient. Short 27-gauge needles
should be used to allow aspiration and minimize tissue
damage.44 In addition, the duration of the infusion of
the local anaesthetic into the tissue should be for a
minimum of 1m with 2m being preferable.45 Periodontal
ligament injections may be used where appropriate.
Besides injections over bone, intraseptal injections are
also considered safe. Injections into highly vascularized
areas such as the sites for the posterior superior
alveolar nerve block, the long buccal nerve and greater
palatine area should be avoided.46 The inferior alveolar
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Table 3. Drugs commonly used in dentistry that
interact with warfarin
Drug Effect on INR
Carbamazepine (Tegretol) Q Q
Metronidazole qq
Sulphonamides (trimethoprim, sulfamethoxazole) qq
Erythromycin q
Miconazole (oral gel) q
Tetracycline q
Note: Prolonged use of any oral antibiotic is not recommended due 
to potential for gut flora suppression and risk of elevated INR due to
vitamin K deficiency.
Aspirin, NSAIDs: increased risk of bleeding due to antiplatelet effect;
avoid concurrent use (except patients at high risk for
thromboembolism).
Local anaesthetic agents, paracetamol, and codeine do not interact
with warfarin.
Table 4. Local measures to control bleeding in
warfarinized patients undergoing dental extractions
• Local anaesthetic
• Controlled, minimally traumatic surgical technique
• Local pressure with gauze packs
• Sutures
• Absorbable packs (e.g., Surgicel®‚ Gelfoam®)
• Tranexamic acid mouthrinse, or
• Fibrin Sealant – autologous or donor based
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nerve block has the greatest potential for a major
complication, as it is possible for a dissecting
haematoma to develop which could occlude the airway.
The Gow-Gates mandibular block technique is
preferable to the conventional inferior alveolar
injection or the Akinosi injection because when
performed correctly, it has the lowest positive
aspiration rate and supplemental injections are not
necessary to anaesthetize the buccal and lingual
gingivae.47 In this case a long needle would be necessary
to place the anaesthetic in the proper location.
2a) Tranexamic acid 
It seems that one of the most significant pathogenic
factors for the development of bleeding after oral surgery
is the activation of fibrinolysis in the oral cavity. In 1989
a study by Sindet-Pederson et al. demonstrated that
maintenance of oral anticoagulant therapy in
conjunction with oral surgery does not result in severe
bleeding complications in patients receiving a tranexamic
acid mouthwash post-operatively.6 Several other studies
have confirmed that anticoagulation treatment does not
need to be withdrawn before oral surgery provided that
local antifibrinolytic therapy is instituted.48-51
Tranexamic acid is the active trans-stereoisomer of
amino-methyl cyclohexane carboxylic acid and has
been shown to have powerful antifibrinolytic
properties. First described by Okamoto and Okamoto
in 1962,52 the molecule is a competitive inhibitor of
plasminogen activation and a non-competitive inhibitor
of plasmin. Tranexamic acid can be administered
systemically or topically. In patients on oral
anticoagulants, systemic treatment is not
recommended, since these patients run a greater risk of
developing thromboembolism. Administration of
10mL of a 4.8 per cent tranexamic acid mouthwash
results in an average concentration of 7µg of
tranexamic acid/mL saliva after two hours, and the
drug remains at detectable levels in the saliva for eight
hours. Since the concentration of tranexamic acid in
plasma is barely detectable after use of the
mouthwash,6,28 there is insignificant inhibition of
systemic fibrinolysis and side effects following this
treatment are not to be expected, provided the patients
follow the directions for using the drug (i.e., do not
swallow it). Tranexamic acid has also been shown to
accelerate normal wound healing.53-54 A 4.8 per cent
mouthwash is available in Australia through the
pharmacy department of major hospitals. Patients are
advised to rinse with 10mL for 2m four times a day for
two to seven days.51 Dentists are able to contact the
Hospital pharmacy departments by phone and obtain
the prepared mouthwash at a cost of approximately
$15 to the patient.
2b) Fibrin sealant
Fibrin sealant has been used for enhancement of
local haemostasis after dental extractions for over two
decades.55-60 Fibrin sealing mimics the last phase of
blood clotting, i.e., the conversion of fibrinogen to
fibrin.60 The preparation may be homologous from a
pooled donor source or autologous, derived from the
patient’s own blood. Several homologous fibrin sealant
preparations exist but concern over possible virus
transmission has excluded their availability in Australia.
The autologous system, which can be prepared through
major hospitals, has two components. The first
component consists of autologous fibrinogen, Factor
XIII, and fibronectin dissolved in a sterile calcium
chloride solution (which had been stored in the frozen
state at –70°C). Bovine thrombin, and an
antifibrinolytic drug (to impede clot degradation by the
fibrinolytic system) make up the second component.
The two components are mixed as they are applied to
the surgical site with specialized fibrin glue applicator
kit (Fibrijet® Micromedics, Minnesota, USA)
comprising a twin syringe assembly (Fig 1). Thrombin
converts fibrinogen to fibrin so that clotting is initiated
and the mixture solidifies. At the same time thrombin
activates factor XIII (in the presence of ionized calcium)
which then catalyses the cross-linkage of fibrin, thus
increasing the strength of the clot. During wound
healing the clot material undergoes gradual lysis and is
completely absorbed within two weeks. Aside from its
adhesive and haemostatic properties, the sealant has
been found to enhance wound healing. Studies
comparing the effectiveness of fibrin sealant in patients
undergoing dental extractions who are therapeutically
anticoagulated with warfarin have shown equally
successful outcomes with respect to haemostasis.61-62
The disadvantages of fibrin sealant include; necessity
for blood donation by the patient (approximately
80mL two to three days prior to the proposed surgery),
lack of ready availability, exclusion of patients allergic
to bovine products (bovine thrombin used); and cost-
currently approximately $300. Current
recommendations for its use in therapeutically
warfarinized patients include non-availability of
tranexamic acid mouthwash, patients likely to be non-
compliant with a mouthwash, and more extensive
dentoalveolar procedures such as cystic enucleations.63
We propose the following chart when presented with
a patient requiring dental extractions who is taking
warfarin (Fig 2):
3) Decreasing the level of anticoagulation or
temporarily discontinuing the anticoagulant
In patients in whom the risk of thromboembolism is
less of a problem, it has been suggested by some that
INR
<2.0 2.0-4.0 >4.0
No modifications required No modifications required No surgical treatment
Use local measures (Table 4) Use local measures (Table 4) Until INR reduced
Notify LMO or cardiologist Notify LMO or cardiologist
Re: sub therapeutic atnicoagulation Re: over anticoagulation
Fig 2. Protocol relating INR to management.
the warfarin should be discontinued a minimum of 48
hours before the surgical visit and re-instituted the day
of surgery.64-65 This group of patients includes those
with previous myocardial infarctions, compensated
congestive heart failure, and controlled atrial
fibrillation. A reduction or cessation protocol delays
necessary dental procedures until the anticoagulation
activity can be titrated to an acceptable level. The
protocol requires the monitoring of the INR (i.e.,
multiple blood tests) until it falls within a more
acceptable range before beginning treatment. The
problem with such a recommendation is that warfarin
has a long half-life (42 hours) as a result of its slow rate
of biotransformation and a high amount of plasma
protein binding. It takes more than one day from the
withdrawal of the drug for the effect to be evident. In
addition even though several texts have recommended
a decreasing dosage or cessation of the drug before
treatment, the number of days suggested for the altered
medication regimen before the initiation of treatment
varies from two to six days.66-68 This increases the risk
of thromboembolism,7,69,70 particularly in patients with
artificial valves.9,14 In addition, the theory of rebound
hypercoagulability after withdrawal of warfarin has
been supported by studies that show increased
thrombin activity after warfarin withdrawal.71-73
Whether or not the rebound phenomenon exists, the
patient is exposed to thromboembolic risk for a longer
period than the reduction or discontinuation of the
warfarin, since it takes a few days for the therapeutic
level to be reached.68 Even when the two-day
withdrawal protocol is followed, the INR should be
determined in the immediate pre-treatment period
because of the known fluctuations of INR even in the
best-maintained patients.
4) Substituting heparin for warfarin
An alternative approach for patients at high risk for
thromboembolism (e.g., prosthetic heart valve
replacement) is to discontinue warfarin and introduce
heparin to achieve an APTT of 1.5 to 2 times the
control. This approach as outlined by Roser and
Rosenbloom,74 requires hospitalization with close
monitoring of the anticoagulant treatment, and is often
a very expensive process. The patient’s warfarin is
ceased 24 hours prior to the admission, and heparin
therapy via an intravenous infusion is instituted upon
admission. As soon as the INR has decreased to a level
appropriate for surgery the patient is scheduled for
surgery with the heparin therapy ceased six hours pre-
operatively. Heparin therapy is recommended 12 to 24
hours post-operatively, depending on the severity of the
surgical procedure. Warfarin is re-instituted on the
night of the operation. The INR is checked on a daily
basis until it is within therapeutic range. When this has
been achieved, heparin therapy is discontinued and the
patient discharged. This inpatient hospital management
protocol usually involves a stay of three to six days at
a financial cost of approximately $3000 to the public
health system as well as a significant social cost to the
patient. In effect, the total time the patient remains
without anticoagulation ranges from 16-24 hours as
opposed to three to four days with the method of
discontinuing and re-instituting warfarin discussed
previously. While this technique is applicable to all
patients on continuous anticoagulant therapy, it is
complex and requires interdisciplinary co-operation,
hence it has only been recommended for the patient
with the greatest risk of thromboembolism and is not
the answer for less complicated surgery or for low risk
patients.
CONCLUSION
In the past, the management of patients
therapeutically anticoagulated with warfarin requiring
dental extractions has posed a dilemma to the attending
dental surgeon. The following factors have probably
contributed to the favourable evolution of the
management of these patients: increased training and
experience of dentists; improved dental status of
patients, minimizing necessity for multiple extractions
and increasing awareness of local fibrinolysis in the
oral cavity and the use of local measures. These
principles have been taught by the authors over the last
decade. They have been tested in formal clinical
trials51,62,63 and used on over a thousand patients
anticoagulated with warfarin. The result is that all
patients can now undergo dental extractions on an
ambulatory basis without interruption of their normal
warfarin regimen. The cost differential is impressive
and obviously represents considerable savings both for
the patient and society. However, more importantly the
elimination of the need for hospitalization and for
multiple venipunctures and infusions provides great
comfort and psychological benefit for the patient.
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